Cardiac-derived extracellular matrix enhances cardiogenic properties of human cardiac progenitor cells

Cell Transplantation

Volumn 25, Issue 9, 2016, Pages 1653-1663

  Gaetani, Roberto ^a   Yin, Christopher ^a   Srikumar, Neha ^a   Braden, Rebecca ^a   Doevendans, Pieter A ^b   Sluijter, Joost P G ^b   Christman, Karen L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiac extracellular matrix; Cardiac progenitor cells (CPCs); Cardiac regeneration; Cardiac tissue engineering

Indexed keywords

ACTIN; CD31 ANTIGEN; COLLAGEN; HYDROGEN PEROXIDE; KI 67 ANTIGEN; MYOCYTE ENHANCER FACTOR 2; MYOCYTE ENHANCER FACTOR 2C; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN 2A; MYOSIN LIGHT CHAIN 2V; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; HOMEOBOX PROTEIN NKX-2.5; NKX2.5 PROTEIN, RAT; POLYETHYLENE GLYCOL DIMETHACRYLATE HYDROGEL; VASCULOTROPIN A;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CARDIAC STEM CELL; CELL CULTURE; CELL ENCAPSULATION; CELL MIGRATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSPLANTATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FETUS; GENE EXPRESSION; HEART FUNCTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEL; IMMUNOFLUORESCENCE; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; STEM CELL; TISSUE ENGINEERING;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; EXTRACELLULAR MATRIX; FEMALE; GATA4 TRANSCRIPTION FACTOR; HOMEOBOX PROTEIN NKX-2.5; HUMANS; HYDROGEL, POLYETHYLENE GLYCOL DIMETHACRYLATE; MEF2 TRANSCRIPTION FACTORS; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; STEM CELLS; TISSUE ENGINEERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84984629339     PISSN: 09636897     EISSN: 15553892     Source Type: Journal    
DOI: 10.3727/096368915X689794     Document Type: Article

References (57)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, et al. Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015; 131(4):e29-322.
2. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet 2012;379(9819):933-42.
3. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol. 2014;11(4):232-46.
4. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Metaanalysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361-77.
5. Gyongyosi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moye LA, Surder D, Corti R, Huikuri H, Miettinen J, Wohrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116(8):1346-60.
6. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, Cossu G, Giacomello A. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95(9):911-21.
7. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marban E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115(7):896-908.
8. Smits AM, van Vliet P, Metz CH, Korfage T, Sluijter JP, Doevendans PA, Goumans MJ. Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: An in vitro model for studying human cardiac physiology and pathophysiology. Nat Protoc. 2009;4(2):232-43.
9. Smits AM, van Laake LW, den Ouden K, Schreurs C, Szuhai K, van Echteld CJ, Mummery CL, Doevendans PA, Goumans MJ. Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovasc Res. 2009;83(3):527-35.
10. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114(6):763-76.
11. Lee ST, White AJ, Matsushita S, Malliaras K, Steenbergen C, Zhang Y, Li TS, Terrovitis J, Yee K, Simsir S, Makkar R, Marban E. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol. 2011;57(4):455-65.
12. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 2013;127(2):213-23.
13. Johnston PV, Sasano T, Mills K, Evers R, Lee ST, Smith RR, Lardo AC, Lai S, Steenbergen C, Gerstenblith G, Lange R, Marban E. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009;120(12):1075-83, 7 p following 1083.
14. Bolli R, Tang XL, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, Jneid H, Rota M, Leri A, Kajstura J. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013;128(2):122-31.
15. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marban L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marban E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 2012; 379(9819): 895-904.
16. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marban L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC, Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110-22.
17. Bolli R, Chugh AR, D’Amario D, Loughran JH, Stoddard MF, Ikram S, Beache GM, Wagner SG, Leri A, Hosoda T, Sanada F, Elmore JB, Goichberg P, Cappetta D, Solankhi NK, Fahsah I, Rokosh DG, Slaughter MS, Kajstura J, Anversa P. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011;378(9806):1847-57.
18. Chugh AR, Beache GM, Loughran JH, Mewton N, Elmore JB, Kajstura J, Pappas P, Tatooles A, Stoddard MF, Lima JA, Slaughter MS, Anversa P, Bolli R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: Surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012;126(11 Suppl 1):S54-64.
19. Mehta A, Shim W. Cardiac stem cell therapy: Stemness or commitment? Cell Transplant. 2013;22(1):1-14.
20. Garbern Jessica C, Lee Richard T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013;12(6):689-98.
21. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9(9):1195-201.
22. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, Dzau VJ. Evidence supporting paracrine hypothesis for Aktmodified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20(6): 661-9.
23. Chimenti I, Smith RR, Li TS, Gerstenblith G, Messina E, Giacomello A, Marban E. Relative roles of direct regeneration versus paracrine effects of human cardiospherederived cells transplanted into infarcted mice. Circ Res. 2010;106(5):971-80.
24. Malliaras K, Zhang Y, Seinfeld J, Galang G, Tseliou E, Cheng K, Sun B, Aminzadeh M, Marban E. Cardiomyocyte proliferation and progenitor cell recruitment underlie therapeutic regeneration after myocardial infarction in the adult mouse heart. EMBO Mol Med. 2013;5(2):191-209.
25. Terrovitis JV, Smith RR, Marban E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010;106(3):479-94.
26. Wu KH, Mo XM, Han ZC, Zhou B. Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg. 2011;92(5):1917-25.
27. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J Mol Cell Cardiol. 2001;33(5):907-21.
28. Radisic M, Christman KL. Materials science and tissue engineering: Repairing the heart. Mayo Clin Proc. 2013; 88(8):884-98.
29. Gaetani R, Rizzitelli G, Chimenti I, Barile L, Forte E, Ionta V, Angelini F, Sluijter JP, Barbetta A, Messina E, Frati G. Cardiospheres and tissue engineering for myocardial regeneration: Potential for clinical application. J Cell Mol Med. 2010;14(5):1071-7.
30. Ye KY, Black LD, III. Strategies for tissue engineering cardiac constructs to affect functional repair following myocardial infarction. J Cardiovasc Transl Res. 2011;4(5):575-91.
31. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44(3):654-60.
32. Guo HD, Wang HJ, Tan YZ, Wu JH. Transplantation of marrow-derived cardiac stem cells carried in fibrin improves cardiac function after myocardial infarction. Tissue Eng Part A 2011;17(1-2):45-58.
33. Danoviz ME, Nakamuta JS, Marques FL, dos Santos L, Alvarenga EC, dos Santos AA, Antonio EL, Schettert IT, Tucci PJ, Krieger JE. Rat adipose tissue-derived stem cells transplantation attenuates cardiac dysfunction post infarction and biopolymers enhance cell retention. PLoS One 2010;5(8):e12077.
34. Lin YD, Yeh ML, Yang YJ, Tsai DC, Chu TY, Shih YY, Chang MY, Liu YW, Tang AC, Chen TY, Luo CY, Chang KC, Chen JH, Wu HL, Hung TK, Hsieh PC. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 2010;122(11 Suppl):S132-41.
35. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 2005;112(9 Suppl):I173-7.
36. Roche ET, Hastings CL, Lewin SA, Shvartsman DE, Brudno Y, Vasilyev NV, O’Brien FJ, Walsh CJ, Duffy GP, Mooney DJ. Comparison of biomaterial delivery vehicles for improving acute retention of stem cells in the infarcted heart. Biomaterials 2014;35(25):6850-8.
37. Gaetani R, Feyen DA, Verhage V, Slaats R, Messina E, Christman KL, Giacomello A, Doevendans PA, Sluijter JP. Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 2015;61:339-48.
38. Kutschka I, Chen IY, Kofidis T, Arai T, von Degenfeld G, Sheikh AY, Hendry SL, Pearl J, Hoyt G, Sista R, Yang PC, Blau HM, Gambhir SS, Robbins RC. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation 2006;114(1 Suppl):I167-73.
39. Feyen D, Gaetani R, Liu J, Noort W, Martens A, den Ouden K, Doevendans PA, Sluijter JP. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013;99(1):83-91.
40. Nakayama KH, Hou L, Huang NF. Role of extracellular matrix signaling cues in modulating cell fate commitment for cardiovascular tissue engineering. Adv Healthc Mater. 2014;3(5):628-41.
41. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126(4):677-89.
42. Hynes RO. The extracellular matrix: Not just pretty fibrils. Science 2009;326(5957):1216-9.
43. Battista S, Guarnieri D, Borselli C, Zeppetelli S, Borzacchiello A, Mayol L, Gerbasio D, Keene DR, Ambrosio L, Netti PA. The effect of matrix composition of 3D constructs on embryonic stem cell differentiation. Biomaterials 2005;26(31):6194-207.
44. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 2009;30(29):5409-16.
45. Singelyn JM, Sundaramurthy P, Johnson TD, Schup-Magoffin PJ, Hu DP, Faulk DM, Wang J, Mayle KM, Bartels K, Salvatore M, Kinsey AM, Demaria AN, Dib N, Christman KL. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J Am Coll Cardiol. 2012; 59(8): 751-63.
46. Seif-Naraghi SB, Singelyn JM, Salvatore MA, Osborn KG, Wang JJ, Sampat U, Kwan OL, Strachan GM, Wong J, Schup-Magoffin PJ, Braden RL, Bartels K, DeQuach JA, Preul M, Kinsey AM, DeMaria AN, Dib N, Christman KL. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med. 2013;5(173):173ra25.
47. DeQuach JA, Mezzano V, Miglani A, Lange S, Keller GM, Sheikh F, Christman KL. Simple and high yielding method for preparing tissue specific extracellular matrix coatings for cell culture. PLoS One 2010;5(9):e13039.
48. French KM, Boopathy AV, DeQuach JA, Chingozha L, Lu H, Christman KL, Davis ME. A naturally derived cardiac extracellular matrix enhances cardiac progenitor cell behavior in vitro. Acta Biomater. 2012;8(12):4357-64.
49. Johnson TD, Dequach JA, Gaetani R, Ungerleider J, Elhag D, Nigam V, Behfar A, Christman KL. Human versus porcine tissue sourcing for an injectable myocardial matrix hydrogel. Biomater Sci. 2014;2014:60283d.
50. Ungerleider JL, Johnson TD, Rao N, Christman KL. Fabrication and characterization of injectable hydrogels derived from decellularized skeletal and cardiac muscle. Methods 2015;84:53-9.
51. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE. Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. Nat Med. 1998;4(8): 929-33.
52. Sanganalmath SK, Bolli R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113(6):810-34.
53. Taylor DA, Sampaio LC, Gobin A. Building new hearts: A review of trends in cardiac tissue engineering. Am J Transplant. 2014;14(11):2448-59.
54. Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: State of the art. Circ Res. 2014;114(2):354-67.
55. Gaetani R, Doevendans PA, Metz CH, Alblas J, Messina E, Giacomello A, Sluijter JP. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. Biomaterials 2012;33(6):1782-90.
56. Chimenti I, Rizzitelli G, Gaetani R, Angelini F, Ionta V, Forte E, Frati G, Schussler O, Barbetta A, Messina E, Dentini M, Giacomello A. Human cardiosphere-seeded gelatin and collagen scaffolds as cardiogenic engineered bioconstructs. Biomaterials 2011;32(35):9271-81.
57. van Marion MH, Bax NA, van Turnhout MC, Mauretti A, van der Schaft DW, Goumans MJ, Bouten CV. Behavior of CMPCs in unidirectional constrained and stress-free 3D hydrogels. J Mol Cell Cardiol. 2015;87:79-91.